Hematologists and other physicians that are involved in the initial and long-term care of patients diagnosed with acquired TTP. Consultant and training haematologists, nephrologist and molecular pathologists.
At the conclusion of this activity, I will be able to:
- To be able to understand the pathophysiology of acquired TTP and its relevance to treatment
- To learn about novel, more targeted approaches to therapy of acquired TTP
- To be able to recognize the presence of long term complications from a prior diagnosis of TTP including neurocognitive changes, headaches, mood disorders, and vascular complications
- To better understand the appropriate long-term follow-up for TTP patients to be able to diagnose these long-term complications and assess the risk for relapse
- Understand the current diagnostic definitions and classification of aHUS and its limitations
- Understand the diversity of genetic lesions known to result in aHUS
- Understand the basic laboratory methodologies used to detect these changes and their strengths and limitations
- Understand the role detection of genetic lesions has in the diagnosis and management of aHUS
|Geoffrey Barnes, MD||Portola||Consulting|
|Blue Cross Blue Shield of Michigan||Research|
|Chris Ward, PhD||Bayer||Speaker|
|Boehringer-Ingelheim||Speaker, Advisory Board|
|BMS/Pfizer||Speaker, Advisory Board|
|Sanofi-Aventis, Alexion||Speaker, Advisory Board|
|Yukio Ozaki||The Sysmex Corporation||Advisory Board|
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.